Health · 20 views
GLP-1-based meds are linked to fewer heart events in adults with obesity, autoimmune disease
Among adults with both obesity and an autoimmune disease, those taking a glucagon-like peptide-receptor 1 agonist (GLP-1RA) medication had lower rates of emergency department visits and were less likely to experience serious cardiac even…
Summary
Among adults with both obesity and an autoimmune disease, those taking a glucagon-like peptide-receptor 1 agonist (GLP-1RA) medication had lower rates of emergency department visits and were less likely to experience serious cardiac events, such as stroke, pulmonary embolism or death when compared to similar adults who were not taking these medications, according to new research published in the Journal of the American Heart Association . This research was presented at the American Diabetes Association 2026 Scientific Sessions in New Orleans.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Australian pollen season may be arriving early in eastern statesContinue reading
- An administrative gap delays access to new pancreatic cancer treatmentContinue reading
- The key to successful treatment of primary aldosteronism: Get it earlyContinue reading
- Children with cancer are being saved, but are we breaking them in the process?Continue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow